Skip to content
About Us
Technology
Pipelines
Team
News
中文
News
Categories
News
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Multitude Therapeutics’ AMT-253 Breakthrough Therapy Designation
2025-12-17
December 17, 2…
Read More →
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
2025-10-19
Multitude Ther…
Read More →
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
2025-10-17
Multitude Ther…
Read More →
